• Sakura Banner


    • Latest news
    • Press releases
    • Upcoming events
news > Press releases > 20210701

Sakura Finetek Japan Signs MOU for Cooperation on Development of Next-Generation Pathology Diagnostic Systems with National Cancer Center Japan


On July 1, Sakura Finetek Japan Co., Ltd. (Sakura Finetek Japan) concluded a Memorandum of Understanding with the Exploratory Oncology Research & Clinical Trial Center (EPOC) of the National Cancer Center Japan for cooperation on the development of next-generation pathology diagnostic systems and diagnosis support systems that leverages the advancements in information technology, and collaboration on research of histology applications for practical use.

EPOC and Sakura Finetek Japan have been exchanging ideas about the importance of appropriate handling of specimens, standardizing of pathology images for diagnosis and the development of next-generation diagnostic systems. This MOU will accelerate the exchange of information and effective use of intellectual, material and human resources on both sides.

EPOC will leverage its network of research and clinical facilities to focus on the development of telepathology and AI and robotics driven, next-generation diagnostic pathology systems by researching the effective use of digital images in pathology diagnosis and integration with other clinical information. Sakura Finetek Japan will cooperate with EPOC on the automation of the specimen preparation process and the standardization of digital pathology images.

■About National Cancer Center Japan Exploratory Oncology Research & Clinical Trial Center
The National Cancer Center Japan, established in 1962, leads the nation’s cancer treatment, prevention, control programs, research, and education as the national core organization in medical care and research of cancer.
The National Cancer Center Japan Exploratory Oncology Research & Clinical Trial Center (NCC-EPOC), established in 2015, aims to Conquer and Cure Cancer (=3C) by comprehensively supporting the development of cancer drugs and medical devices from the seeds discovery phase up to the preclinical or early clinical trial phases. EPOC has an excellent track record of introducing advanced cancer treatment to clinical use through close cooperation with the National Cancer Center Hospital East (NCCHE).

・National Cancer Center Japan Exploratory Oncology Research & Clinical Trial Center

■Sakura Finetek Group Mission
Advancing cancer diagnostics by providing integrated solutions for anatomic pathology and patient 
through best-in-class innovation, quality and customer care.

Sakura Finetek Japan is committed to its mission of advancing cancer diagnosis globally and provides solutions to customers in over 150 countries together with Sakura Finetek USA, Sakura Finetek Europe, Sakura Medical Science Technology (Taizhou) Co., Ltd in China.

In addition to developing and delivering pathology solutions, we provide technical training and application services to assist our customers in the routine preparation of histology and cytology specimens.